However, no previous study has validated KL-6 in distinguishing TR-ILD from pneumonia or non-ILD events at the onset of adverse events similar to ILD after cancer treatment19, which can be encountered in actual clinical practice. Here, MUC1 is linked to susceptibility to pneumonia measurement.